Intestinal levels of FXR are significantly downregulated in CRC patients, and its expression has an inverse correlation with the progression of CRC, mainly attributed to DNA methylation and KRAS signaling (Sun et al., 2021). The gene discussed is NR1H4; the disease is colorectal carcinoma.